SEARCH

SEARCH BY CITATION

References

  • 1
    Schuster SJ, Koury ST, Bohler M, Salceda S, Card J. Cellular sites of extrarenal and renal erythropoietin production in anaemic rats. Br. J. Haematol. 1992; 81; 153159.
  • 2
    Lacombe C, Mateux P. Biology of erythropoietin. Haematologica 1998; 83; 724732.
  • 3
    Ribatti D, Vacca A, Roccaro AM, Crivellato E, Presta M. Erythropoietin as an angiogenic factor. Eur. J. Clin. Invest. 2003; 33; 891896.
  • 4
    Anagnostou A, Liu Z, Steiner M et al. Erythropoietin receptor mRNA expression in human endothelial cells. Proc. Natl Acad. Sci. USA 1994; 91; 39743978.
  • 5
    Anagnostou A, Lee ES, Kessimian N, Levinson R, Steiner M. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc. Natl Acad. Sci. USA 1990; 87; 58785982.
  • 6
    Ashley RA, Dubuque SH, Dvorak B, Woodward SS, Williams SK, Kling PJ. Erythropoietin stimulates vasculogenesis in neonatal rat mesenteric microvascular endothelial cells. Pediatr. Res. 2002; 51; 472478.
  • 7
    Carlini RG, Reyes AA, Rothstein A. Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Int. 1995; 47; 740748.
  • 8
    Ribatti D, Presta M, Vacca A et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 1999; 93; 26272636.
  • 9
    Jaquet K, Krause K, Tawakol-Khodai M, Geidel S, Kuch KM. Eryhropoietin and VEGF exhibit angiogenic potential. Microvasc. Res. 2002; 64; 326333.
  • 10
    Semela D, Dufour JF. Angiogenesis and hepatocellular carcinoma. J. Hepatol. 2004; 41; 864880.
  • 11
    Zacharoulis D, Hatzitheofilou C, Athanasiou E, Zacharoulis S. Antiangiogenic strategies in hepatocellular carcinoma: current status. Expert Rev. Anticancer Ther. 2005; 5; 645656.
  • 12
    Sakamoto M, Ino Y, Fujii T, Hirohashi S. Phenotype changes in tumor vessels associated with the progression of hepatocellular carcinoma. Jpn J. Clin. Oncol. 1993; 23; 98104.
  • 13
    Horak ER, Leek R, Kenk N et al. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 1992; 340; 11201124.
  • 14
    Vacca A, Ribatti D, Roncali L et al. Melanocyte tumor progression is associated with changes in angiogenesis and expression of the 67-kilodalton laminin receptor. Cancer 1993; 72; 455461.
  • 15
    Ribatti D, Nico B, Vacca A et al. Do mast cells help to induce angiogenesis in B-cell non Hodgkin's lymphoma? Br. J. Cancer 1998; 77; 19001906.
  • 16
    Kayser K, Gabius HJ. Analysis of expression of erythropoietin-binding sites in human lung carcinoma by the biotinylated ligand. Zentrabl. Pathol. 1992; 138; 266270.
  • 17
    Westenfelder C, Baranowski RL. Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int. 2000; 58; 647657.
  • 18
    Yasuda Y, Musha T, Tanaka H et al. Inhibition of erythropoietin signalling destroys xenografts of ovarian and uterine cancers in nude mice. Br. J. Cancer 2001; 84; 836843.
  • 19
    Yasuda Y, Fujita Y, Masuda S et al. Erythropoietin is involved in growth and angiogenesis in malignant tumors of female reproductive organs. Carcinogenesis 2002; 23; 17971805.
  • 20
    Acs G, Zhang PJ, McGrath CM et al. Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. Am. J. Pathol. 2003; 162; 17891806.
  • 21
    Batra S, Perelman N, Luck LR, Shimada H, Malik P. Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival. Lab. Invest. 2003; 83; 14771487.
  • 22
    Hengartner MO, Horvitz HR. C. elegans cell survival gene ced-9 encodes a functional homolog of the mammalian proto-oncogene bcl-2. Cell 1994; 76; 665676.
  • 23
    Acs G, Zhang PJ, Rebbeck TR, Acs P, Verna A. Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma. Cancer 2002; 95; 969981.
  • 24
    Arcasoy MO, Amin K, Karayal AF et al. Functional significance of erythropoietin receptor expression in breast cancer. Lab. Invest. 2002; 82; 911918.
  • 25
    Dillard DG, Venkatraman G, Cohen C, Delgaudio J, Gal AA, Mattox DE. Immunolocalization of erythropoietin and erythropoietin receptor in vestibular schwannoma. Acta Otolaryngol. 2001; 121; 149152.
  • 26
    Yasuda Y, Fujita Y, Matsuo T et al. Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 2003; 24; 10211029.
  • 27
    Okabe T, Urabe A, Kato T, Chiba S, Takaku F. Production of erythropoietin-like activity by human renal and hepatic carcinoma in cell culture. Cancer 1985; 55; 19181923.
  • 28
    Matsuyama M, Yamazaki O, Horii K et al. Erythrocytosis caused by an erythropoietin-producing hepatocellular carcinoma. J. Surg. Oncol. 2000; 75; 197202.
  • 29
    Sugimachi K, Tanaka S, Taguchi K et al. Angiopoietin switching regulates angiogenesis and progression of human hepatocellular carcinoma. J. Clin. Pathol. 2003; 56; 854860.
  • 30
    Nakamatsu K, Nishimura Y, Suzuki M, Kanamori S, Maenishi O, Yasuda Y. Erythropoietin/erythropoietin-receptor system as an angiogenic factor in chemically induced hepatic tumors. Int. J. Clin. Oncol. 2004; 9; 184188.